« Back
Home /
CDDD11-8

CDDD11-8

Item no.	HY-162037-25mg
Manufacturer	MedChem Express
CASRN	2241659-94-7
Amount	25 mg
Quantity options	1 ea 100 mg 10 mg 25 mg 50 mg 5 mg
Category	Reagents & Chemicals Standards, Ladders & Markers
Type	Standard
Specific against	other
Purity	99.62
Citations	[1]Anshabo AT, et al. An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia. Cancers (Basel). 2022 Feb 22;14(5):1113.\|[2]Mustafa EH, et al. Selective inhibition of CDK9 in triple negative breast cancer. Oncogene. 2023 Nov 24.
Smiles	CC1=CN=C(N[C@@H]2CC[C@@H](N)CC2)N=C1C3=CN=C(C=C4)N3C=C4C5=CC=CC=C5
ECLASS 10.1	42021590
ECLASS 11.0	42021590
UNSPSC	12352202
Shipping Condition	Cool pack
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	CDK; FLT3
Shipping Temperature	Blue Ice
Storage Conditions	-20°C, 3 years (Powder)
Molecular Weight	398.50
Product Description	CDDD11-8 is an orally active, potent and selective inhibitor of CDK9 and FLT3-ITD, with Ki values of 8 and 13 nM, respectively. CDDD11-8 reduces the proliferation of leukemia cell lines and was particularly effective against those harboring FLT3-ITD mutation[1][2].
Manufacturer - Research Area	Cancer
Solubility	10 mM in DMSO
Manufacturer - Pathway	Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK
Clinical information	No Development Reported
Isoform	CDK9

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-162037-25mg-safety-datasheet.pdf